Blog

News

Press Release

SA’s Kardio Group recognized for leadership strategy

25 April, 2019: Based on its recent analysis of the South African Internet of Medical Things (IOMT) market, London-based growth partnership organisation, Frost and Sullivan, has recognized Kardio Group with the 2019 South Africa Product Line Strategy Leadership Award. 

Each year Frost and Sullivan presents this award to the company that develops a comprehensive product line that caters to the breadth of the market it serves. The award recognises the extent to which the product line meets customer base demands, and the overall impact it has in terms of customer value and increased market share.

In the award announcement, it was noted that: “Kardio Group’s sophisticated online platform and ecosystem of integrated, connected devices as well as its impressive list of partners give it a distinct competitive edge in a complex market. Its solutions accurately predict risks and monitor non-communicable diseases (NCDs) such as hypertension, diabetes, obesity, asthma, and chronic obstructive pulmonary disease (COPD).”

Adding to this, Nicholas Burger, Ph.D., Consultant at Frost and Sullivan, said: “The Kardio Group leverages advanced technology to offer one of the world’s most precise and advanced toolkits for monitoring and assessing NCD risk. Kardio Group excels in innovation geared towards patients such as home monitoring via its Kardiofit solution, as well as in-practice diagnostic, risk stratification, and disease management via its KardioPro solution.

The company, led by CEO Dr Riaz Motara (above), also partners with iHealth, a global health informatics company that designs fitness tracking and health monitoring devices, as well as with ER24, an ambulance service to assist patients with cardiovascular emergencies detected through remote monitoring.”

Kardio Group’s solutions are fully automated with cloud-based storage of all health data. For instance, Kardiofit is a Bluetooth home-based monitoring solution for patients with hypertension, diabetes, asthma, and COPD that links to emergency care. 

KardioPro is a practice-based solution that connects a suite of point-of-care (POC) devices to measure an array of vital signs with the company’s online platform. Medical practitioners can utilise KardioPro to capture health data accurately. Captured metrics include pulse, blood pressure, stroke volume, cardiac output, and the ankle-brachial index. The system also calculates and tracks body mass index, blood oxygen saturation (oximetry), and blood glucose levels.

Additionally, the system allows practitioners to assess a patient’s cholesterol, HbA1c, renal function, and urine protein levels through validated POC devices. KardioPro permits physicians to visualise, analyse, and share data from their offices or while on the move, thereby improving adherence and fostering streamlined doctor-patient interactions.

SOURCE:
Frost and Sullivan Communication

Press Release

Solutions for the Management of Non-communicable Diseases

London, 23 April, 2019: Based on its recent analysis of the South African Internet of Medical Things (IOMT) market, Frost & Sullivan recognises Kardio Group with the 2019 South Africa Product Line Strategy Leadership Award.

The company’s sophisticated online platform and ecosystem of integrated, connected devices as well as its impressive list of partners give it a distinct competitive edge in a complex market. Its solutions accurately predict risks and monitor non-communicable diseases (NCDs) such as hypertension, diabetes, obesity, asthma, and chronic obstructive pulmonary disease (COPD). “The Kardio Group leverages advanced technology to offer one of the world’s most precise and advanced toolkits for monitoring and assessing NCD risk. Kardio Group excels in innovation geared toward patient home monitoring via its Kardio􀁾t solution, as well as in-practice diagnostic, risk stratification, and disease management via its KardioPro solution,” said Nicholas Burger, Ph.D., Consultant at Frost & Sullivan. “Kardio Group partners with iHealth, a global health informatics company that designs Fitness tracking and health monitoring devices, as well as with ER24, an ambulance service to assist patients with cardiovascular emergencies detected through remote monitoring.”

The company understands the need to move beyond generalised wellness and to focus on patient-centric solutions that include predictive analytics. Kardio Group’s solutions are fully automated with cloud-based storage of all health data. For instance, Kardio􀁾t is a Bluetooth home-based monitoring solution for patients with hypertension, diabetes, asthma, and COPD that links to emergency care. KardioPro, meanwhile, is a practice-based solution that connects a suite of point-of-care (POC) devices to measure an array of vital signs with the company’s online platform.

Medical practitioners can utilise KardioPro to capture health data accurately. Captured metrics include pulse, blood pressure, stroke volume, cardiac output, and the ankle-brachial index. KardioPro also calculates and tracks body mass index, blood oxygen saturation (oximetry), and blood glucose levels. Additionally, the system allows practitioners to assess a patient’s cholesterol, HbA1c, renal function, and urine protein levels through validated POC devices. KardioPro permits physicians to visualise, analyse, and share data from their offices or while on the move, thereby improving adherence and fostering streamlined doctor patient interactions.

“The Kardio Group designed its product portfolio to accommodate different needs and Financial capacities, and it offers both software and hardware solutions to healthcare practices and individual practitioners via a subscription model,” noted Dr. Burger. “Kardio Group has plans to address mental illnesses affecting millions of South Africans, which it aims to integrate as a health focus. Currently, the company serves the private sector but intends to expand into the public sector in the next few years.”

Each year, Frost & Sullivan presents this award to the company that develops a comprehensive product line that caters to the breadth of the market it serves. The award recognises the extent to which the product line meets customer base demands, and the overall impact it has in terms of customer value and increased market share.

About Brandmed:

Brandmed (Pty) Limited is a South African digital health healthcare company founded in 2014 with a vision to create a global people-centric, integrated, value-based, outcome inspired health ecosystem. This vision is underpinned by visionary leaders who care, simple, validated and sustainable solution driven technologies. Brandmed is a world first in delivering a unique fully integrated end to end solution to address outcomes and value-based care for patients with chronic lifestyle and Non- Communicable- Diseases (NCDs) such as hypertension, diabetes, high cholesterol, asthma and chronic obstructive pulmonary disease.

The KardioGroup ecosystem, developed in South Africa, seamlessly integrates a combination of connected solutions across the health continuum for patients, healthcare professionals, practices and institutions, and aims to deliver personalised patient care. This is achieved through key entities of the KardioGroup ecosystem such as, KardioFit, KardioPro, KardioLife and KardioLytix.

KardioFit an automated patient disease management, engagement and monitoring suite to empower patients to actively manage their own health in an era of the quantified self and assists medical professionals to make better informed decisions based on real world experience, resulting in improved clinical outcomes and efficiencies.

KardioPro is an integrated provider/practice point of care suite allowing for real time validated and accurate wireless collection of clinical biometrics. The solution backed by accepted Global and South African Guidelines, automatically guides data interpretation, predictive risk profile analysis and diagnosis to inform standardised, personalised patient treatment and management.

KardioLife is a unique anti-inflammatory lifestyle program.

KardioLytix provides real-time actuarial analyses of all data parameters in the Brandmed ecosystem. With the data generated on unified standards and formats, KardioLytix caters for objective measurement of value-based care outcomes.

About Frost & Sullivan:

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion.

Press Release

CIPLA MEDPRO ACQUIRES A STAKE IN CONNECTED HEALTH COMPANY…

Cape Town, 16 April 2019: In recognition of the importance of the critical shift to a more patient-centric, integrated and predictive healthcare environment, Cipla Medpro South Africa (Pty) Limited (“Cipla Medpro”), wholly-owned subsidiary of Cipla Limited (BSE: 500087; NSE: CIPLA EQ; hereafter referred to as “Cipla”) and South Africa’s third largest pharmaceutical company in the private sector, will acquire a 30% stake upon closure in the connected healthcare company, Brandmed (Pty) Limited. In February, Cipla had announced a similar partnership in India with Wellthy Therapeutics to offer a clinically-validated digital disease management platform to patients in cardio-metabolic health.

Brandmed, founded in 2014, has developed a unique fully integrated end to end solution to address outcomes and value-based care for patients with chronic lifestyle and Non-Communicable- Diseases (NCDs) such as hypertension, diabetes, high cholesterol, asthma and chronic obstructive pulmonary disease. KardioGroup, a subsidiary of Brandmed was awarded the prestigious Frost & Sullivan South African Product Line Strategy Leadership, Internet of Medical Things South Africa, award in 2019.

The Brandmed ecosystem, developed in South Africa, seamlessly integrates a combination of connected solutions across the health continuum for patients, healthcare professionals, practices and institutions, and aims to deliver personalised patient care.

Paul Miller, CEO of Cipla Medpro, said: “This transaction will help to transition healthcare from being reactive to a proactive and real-time monitoring model that focuses on promoting wellness instead of managing illness. This aligns with Cipla’s vision and focus on ‘human care’ and a future where good health is expected, not for the few, but for the many.”

“By pairing our strengths with Brandmed’ s innovative, patient centric approach to healthcare, Cipla Medpro will enhance its diverse portfolio in the NCD area to provide holistic care to patients from awareness through to disease management, thereby enabling patient adherence and compliance.”

The brainchild behind Brandmed, cardiologist Dr Riaz Motara, said: “Drugs alone are not enough to manage a disease and the disease burden will become unmanageable unless innovative solutions are implemented.”

“We’re integrating medical expertise with ground-breaking technology to deliver better patient care and offer an integrated disease management solution. We’re also shifting the focus from managing diseases in separate silos to a comprehensive risk reduction and treatment approach. Greater success in patient health outcomes, value-based care and efficiencies could be achieved in South Africa if more healthcare stakeholders are willing to work together,” said Motara.

The Indigo Wellness Index report reveals that South Africa has tremendous scope for improvement on various health indicators. Measures captured included healthy life expectancy, blood pressure, blood glucose (diabetes risk), obesity, depression, happiness, alcohol use, tobacco use, inactivity (too little exercise), and government spending on healthcare.

According to the World Health Organisation, NCDs – mainly cardiovascular diseases, cancers, chronic respiratory diseases, and diabetes – are the leading cause of death worldwide. More than 38 million people die annually from NCDs (63% of global deaths), including 16 million people who die before the age of 70. Nearly 50% of global disability is attributed to NCDs. Reducing the avoidable burden caused by NCDs and their risk factors means taking actions now to change the narrative around NCDs.

References:

  • https://ww2.frost.com/about/best-practices-recognition
  • http://global-perspectives.org.uk/volume-one/infographics/
  • https://www.who.int/beat-ncds/en/

About Cipla

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology and CNS segments are well-known. Our 44 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Dec’18), 3rd largest in the pharma private market in South Africa (IQVIA YTD Dec’18), and is among the most dispensed generic players in the US. For over eight decades, making a difference to patients has inspired every aspect of Cipla’s work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the movement. A responsible corporate citizen, Cipla’s humanitarian approach to healthcare in pursuit of its purpose of ‘Caring for Life’ and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit www.cipla.com, or click on Twitter, Facebook, LinkedIn.

About Cipla in South Africa

Cipla Medpro South Africa (Pty) Limited is a wholly owned subsidiary of Cipla Limited, India and third largest pharmaceutical company in the private sector in South Africa. Through Cipla’s purpose of ‘Caring for Life’, Cipla Medpro produces world-class medicines at affordable prices for the public and private sectors, advancing healthcare for all South Africans. For more information, visit www.cipla.co.za.

About Brandmed

Brandmed (Pty) Limited is a South African digital health healthcare company founded in 2014 with a vision to create a global people-centric, integrated, value-based, outcome inspired health ecosystem. This vision is underpinned by visionary leaders who care, simple, validated and sustainable solution driven technologies. Brandmed is a world first in delivering a unique fully integrated end to end solution to address outcomes and value-based care for patients with chronic lifestyle and Non- Communicable- Diseases (NCDs) such as hypertension, diabetes, high cholesterol, asthma and chronic obstructive pulmonary disease.

The KardioGroup ecosystem, developed in South Africa, seamlessly integrates a combination of connected solutions across the health continuum for patients, healthcare professionals, practices and institutions, and aims to deliver personalised patient care. This is achieved through key entities of the KardioGroup ecosystem such as, KardioFit, KardioPro, KardioLife and KardioLytix.

KardioFit an automated patient disease management, engagement and monitoring suite to empower patients to actively manage their own health in an era of the quantified self and assists medical professionals to make better informed decisions based on real world experience, resulting in improved clinical outcomes and efficiencies.

KardioPro is an integrated provider/practice point of care suite allowing for real time validated and accurate wireless collection of clinical biometrics. The solution backed by accepted Global and South African Guidelines, automatically guides data interpretation, predictive risk profile analysis and diagnosis to inform standardised, personalised patient treatment and management.

KardioLife is a unique anti-inflammatory lifestyle program.

KardioLytix provides real-time actuarial analyses of all data parameters in the Brandmed ecosystem. With the data generated on unified standards and formats, KardioLytix caters for objective measurement of value-based care outcomes.